Amgen Inc. $AMGN Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 4.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 65,975 shares of the medical research company’s stock after selling 3,034 shares during the quarter. State of Alaska Department of Revenue’s holdings in Amgen were worth $18,617,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Brighton Jones LLC lifted its position in shares of Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after buying an additional 5,226 shares during the last quarter. Caxton Associates LLP acquired a new stake in shares of Amgen in the 1st quarter worth $535,000. Bayforest Capital Ltd purchased a new stake in Amgen in the 1st quarter valued at approximately $41,000. Advisory Alpha LLC boosted its stake in shares of Amgen by 12.2% in the first quarter. Advisory Alpha LLC now owns 919 shares of the medical research company’s stock valued at $286,000 after buying an additional 100 shares in the last quarter. Finally, Integrity Alliance LLC. grew its stake in shares of Amgen by 66.2% during the 1st quarter. Integrity Alliance LLC. now owns 8,436 shares of the medical research company’s stock worth $2,628,000 after purchasing an additional 3,359 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Performance

AMGN stock opened at $330.11 on Friday. Amgen Inc. has a 1 year low of $260.55 and a 1 year high of $346.38. The stock has a market capitalization of $177.76 billion, a price-to-earnings ratio of 25.51, a PEG ratio of 3.11 and a beta of 0.45. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28. The stock’s fifty day moving average is $329.19 and its two-hundred day moving average is $303.93.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating the consensus estimate of $5.01 by $0.63. The firm had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. Amgen’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same period last year, the firm posted $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be paid a dividend of $2.52 per share. This is a boost from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is 73.57%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. UBS Group upgraded shares of Amgen to a “strong-buy” rating in a research report on Wednesday. DZ Bank boosted their target price on Amgen from $335.00 to $364.00 in a report on Monday, November 10th. Guggenheim increased their price target on Amgen from $288.00 to $305.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. Finally, Bank of America raised their price objective on Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research note on Friday, September 26th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $338.55.

Insider Transactions at Amgen

In related news, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the transaction, the executive vice president directly owned 41,923 shares in the company, valued at $14,120,924.09. The trade was a 14.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the sale, the senior vice president directly owned 7,225 shares in the company, valued at $2,436,703.50. This trade represents a 30.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 10,908 shares of company stock valued at $3,674,966. Corporate insiders own 0.76% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.